{"changes":[],"country":"DE","description":"akribion.de refused the connection at fetch time; per the .com property Akribion develops the G-dase E RNA-guided nuclease for programmable cell depletion in precision oncology. It targets clinicians treating HPV-induced head-and-neck cancers initially. Differentiator: single-nucleotide specificity with rapid gRNA retargeting.","domain":"akribion.de","employees":null,"founded":2022,"fundingTotalQuarantined":false,"githubOrg":null,"githubStars":null,"industry":"bio","investors":[],"lat":49.7242,"lng":8.5915,"location":"Zwingenberg, Germany","name":"Akribion Therapeutics","rounds":[{"amountQuarantined":false,"amountUsd":8640000,"currency":"EUR","date":"2025-02-01","investors":[],"leadInvestor":null,"source":{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-16","status":"attributed","url":null},"status":"attributed","type":"seed","url":null}],"slug":"akribion-de","sources":[{"fact":"round","publisher":"sifted","retrievedAt":"2026-05-16","status":"attributed","url":null},{"fact":"existence","publisher":"akribion.de","retrievedAt":"2026-05-16","status":"self-reported","url":"https://akribion.de"},{"fact":"description","publisher":"akribion.de","retrievedAt":"2026-05-16","status":"self-reported","url":"https://akribion.de"}],"stage":"seed","techStack":[],"totalRaisedUsd":8640000,"updatedAt":"2026-05-16"}